EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
What To Know: Jay Woods, chief market strategist at Drive Wealth and NYSE executive floor director, highlighted opportunities in biotech and health care stocks Wednesday on Benzinga's "Stock Market Movers."
"We're starting to see some strength there," Woods said.
Biogen Inc (NASDAQ:BIIB) was one of the stocks Woods focused on.
"We're seeing some technical progress," he said. "I'm starting to see some green shoots there."
Related Link: Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
When screening the sector for stocks with favorable technical setups showing relative strength, three names jumped out at Woods: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Meridian Bioscience Inc (NASDAQ:VIVO) and Harmony Biosciences Holdings Inc (NASDAQ:HRMY).
"These are three little stocks in the sector that are starting to, you know, from a relative basis, act extremely well. And from a technical basis, you know, we're knocking on new highs and that's what I like to see," Woods said.
"If you are looking for stocks from a relative basis that are starting to outperform ... I think biotech and health care are some of the areas that you want to focus on."
Woods went on to name several health care names that are starting to look attractive.
Watch the full interview below to get the rest of Woods' stock picks:
Photo via Shutterstock.
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
在通胀上升和美联储不确定性的背景下，市场继续走低，但纽约证交所的一个大厅董事表示，一些遭受重创的板块可能已经触底。
What To Know: Jay Woods, chief market strategist at Drive Wealth and NYSE executive floor director, highlighted opportunities in biotech and health care stocks Wednesday on Benzinga's "Stock Market Movers."
要知道的内容： 杰伊·伍兹，Drive Wealth首席市场策略师和纽约证交所高管大厅董事周三在Benzinga的《股市交易者》节目中强调了生物科技和医疗保健类股的机会。
"We're starting to see some strength there," Woods said.
“我们开始看到一些力量，”伍兹说。
Biogen Inc (NASDAQ:BIIB) was one of the stocks Woods focused on.
生物遗传公司纳斯达克(Sequoia Capital：BIIB)是伍兹关注的股票之一。
"We're seeing some technical progress," he said. "I'm starting to see some green shoots there."
“我们看到了一些技术上的进步，”他说。“我开始看到一些复苏的萌芽。”
Related Link: Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
相关链接：以下是15年前投资于生物遗传公司的100美元今天的价值
When screening the sector for stocks with favorable technical setups showing relative strength, three names jumped out at Woods: Ionis Pharmaceuticals Inc (NASDAQ:IONS), Meridian Bioscience Inc (NASDAQ:VIVO) and Harmony Biosciences Holdings Inc (NASDAQ:HRMY).
在筛选具有相对强势的有利技术设置的股票时，伍兹突然出现了三个名字：爱奥尼斯制药公司 INC(纳斯达克：Ions)，子午线生物科学公司(纳斯达克：vivo)和和谐生物科学控股有限公司(纳斯达克：HRMY)。
"These are three little stocks in the sector that are starting to, you know, from a relative basis, act extremely well. And from a technical basis, you know, we're knocking on new highs and that's what I like to see," Woods said.
伍兹表示：“这是该板块中的三只小股票，从相对基础上看，它们的表现非常好。从技术基础上看，我们正在创下新高，这是我希望看到的。”
"If you are looking for stocks from a relative basis that are starting to outperform ... I think biotech and health care are some of the areas that you want to focus on."
“如果你在相对的基础上寻找开始跑赢大盘的股票……我认为生物科技和医疗保健是你想要关注的一些领域。”
Woods went on to name several health care names that are starting to look attractive.
伍兹接着列举了几个看起来开始有吸引力的医疗保健公司。
Watch the full interview below to get the rest of Woods' stock picks:
请看下面的完整采访，了解伍兹的其他股票选择：
Photo via Shutterstock.
照片来自Shutterstock。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧